<DOC>
	<DOCNO>NCT01925417</DOCNO>
	<brief_summary>This study assess safety new biologic drug , RBX2660 ( microbiota suspension ) treatment recurrent Clostridium difficile-associated diarrhea ( CDAD ) , primary symptom recurrent Clostridium difficile infection . All eligible subject receive RBX2660 .</brief_summary>
	<brief_title>Microbiota Restoration Therapy Recurrent Clostridium Difficile-associated Diarrhea</brief_title>
	<detailed_description>This first study microbiota suspension derive intestinal microbe . The primary assessment open label , multi-center study ( ) occurrence product-related adverse event ( ii ) resolution CDAD 56 day administration RBX2660 . Subjects also assess time CDAD recurrence , quality life change , number hospitalization length stay recurrent CDAD . Study visit 7 , 30 , 60 day RBX2660 administration additional follow-up 3 6 month post treatment . Patients least two recurrence CDAD primary episode complete least two round standard-of-care oral antibiotic therapy least two episode severe CDAD result hospitalization may eligible study .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<criteria>≥ 18 year Medical record documentation CDAD either : ) least two recurrence primary episode complete least two round standardofcare oral antibiotic therapy b ) least two episode severe CDAD result hospitalization . Willing able enema ( ) . Already take start course oral antibiotic CDAD symptom 1014 day , include least seven day oral vancomycin . Willing able complete require subject diary . Continued ( uncontrolled ) CDAD complete 1014 day course oral antibiotic . Requires antibiotic therapy condition CDAD . Previous fecal transplant prior study enrollment . History inflammatory bowel disease ( IBD ) , e.g. , ulcerative colitis , Crohn 's disease , microscopic colitis . History irritable bowel syndrome ( IBS ) . History chronic diarrhea . History celiac disease . History cirrhosis liver ascites . Disease symptom cause confirmed intestinal pathogen Clostridium difficile . Has colostomy . Intraabdominal surgery within last 60 day . Evidence active , severe colitis . History short gut syndrome motility disorder . Requires regular use medication affect bowel motility ( e.g. , metoclopramide , narcotic , loperamide ) . Planned therapy next 3 month may cause diarrhea ( e.g. , chemotherapy ) . Planned surgery require perioperative antibiotic within 6 month study enrollment . Life expectancy &lt; 12 month . Compromised immune system , e.g. , HIV infection ( CD4 count ) ; AIDSdefining diagnosis CD4 &lt; 200/mm3 ; inherited/primary immune disorder ; immunodeficient immunosuppressed due medical condition medication ; current recent ( &lt; 90 day ) treatment chemotherapy ; current recent ( &lt; 90 day ) treatment immunosuppressant medication . Taking steroid ( ≥ 20 mg day ) expect steroid 30 day enrollment . Neutropenia ( white blood cell count &lt; 1000 cells/µL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>C diff</keyword>
	<keyword>Microbiota Restoration Therapy</keyword>
	<keyword>MRT</keyword>
	<keyword>microbiota suspension</keyword>
	<keyword>CDI</keyword>
	<keyword>CDAD</keyword>
	<keyword>Fecal transplant</keyword>
	<keyword>Fecal Microbiota Transplant</keyword>
	<keyword>FMT</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Fecal bacteriotherapy</keyword>
</DOC>